Dr. Matthew Johnson: Psychedelics for Treating Mental Disorders | Huberman Lab Podcast #38

This episode I discuss medical research on psychedelic compounds with Dr. Matthew Johnson, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine. We discuss the biology of MDMA, LSD, psilocybin and ayahuasca. Dr. Johnson shares the results of clinical trials in his laboratory that reveal the potential of these compounds for treating depression, addiction, eating disorders, ADHD and other mental disorders. Dr. Johnson explains how he conducts a typical psychedelic experiment at his lab, from start to finish. He also outlines the conditions necessary for optimal clinical results. He also explains the dangers, common myths, and pitfalls of psychedelic medicine. Dr. Johnson discusses flashbacks, the increased risks for certain age groups and people using psychedelics, and the constantly changing legal and pharmaceutical industry landscape around psychedelics. Dr. Johnson also discusses how scientific research on psychedelics will determine the future direction of psychiatric medicine. Johnson is one of a few researchers who pioneered clinical research on these powerful compounds. Johnson has unparalleled insight into the ways these compounds can be integrated into other psychiatric treatments. This allows for a change in one’s perception of self and reality.

We are grateful to our sponsors:
Athletic Greens –
Belcampo – n
InsideTracker –

Dr. Matthew Johnson Social Media
Twitter: r
Instagram: r

Our Patreon page
n

Supplements from Thorne
n

Social:
Instagram – b
Twitter – b
Facebook – b
Website – m
Newsletter – k

Links:
Website of Dr. Johnson at Johns Hopkins School of Medicine. n
Chris Letheby’s upcoming book

Timestamps:
00: 00: 00 Introducing Dr. Matthew Johnson
00: 02: 10 Supporting Sponsors
00: 06: 40 ‘Psychedelics’ Defined
00: 14: 09 Hallucinations, Synesthesia, Altered Space-Time Perception
00: 19: 56 Serotonin & Dopamine
00: 23: 50 Ketamine & Glutamate
00: 28: 00 An Example Psychedelic Experiment
00: 37: 30 ‘Letting Go’ with Psychedelics
00: 44: 10 Our Mind’s Eye
00: 48: 00 Redefining Your Sense of Self
00: 58: 56 Exporting Psychedelic Learnings to Daily Life
01: 04: 36 Flashbacks
01: 12: 10 Ayahuasca, & ASMR, Kundalini Breathing
01: 15: 54 MDMA, DMT
01: 26: 00 Dangers of Psychedelics, Bad Trips, Long-Lasting Psychosis
01: 38: 15 Micro-Dosing
01: 56: 45 Risks for Kids, Adolescents & Teenagers; Future Clinical Trials
02: 03: 40 Legal Status: Decriminalization vs. Legalization vs. Regulation
02: 18: 35 Psychedelics for Treating Concussion & Traumatic Brain Injury
02: 27: 45 Shifting Trends in Psychedelic Research, Academic Culture
02: 44: 23 Participating in a Clinical Trial, Online Survey Studies, Breathwork
02: 50: 38 Conclusions, Subscribing & Supporting the HLP, Supplements

The Huberman Lab Podcast does not include Dr. Huberman’s research and teaching roles at Stanford University School of Medicine. This podcast is not intended to replace medical advice. The Huberman Lab Podcast, its guests, and affiliates, assume no responsibility for the use of the information.

Photo credit for Title Card: Mike Blabac – m

http://adhdadulttreatment.com/dr-matthew-johnson-psychedelics-for-treating-mental-disorders-huberman-lab-podcast-38/

Attention deficit hyperactivity disorder (ADHD) is a commonly misunderstood mental health condition. This video explains ADHD and the symptoms (ADD and ADHD). The video also addresses the treatment options available to treat ADHD symptoms, including medication and psychotherapy. The video also touches on research that has highlighted the benefits of using video games to treat ADHD symptoms.

This video was created by McMaster students Abhitikuhad, Veronica Iskander and Sundas Ramzan in collaboration with McMaster Demystifying Medicine Program .
Subscribe to McMaster Demystifying medicine YouTube channel: e

This video is intended for educational purposes only. For information about your health, please consult your doctor.

Copyright McMaster University 2019

#DemystifyingMedicine, #MentalHealth
References:

Ramtekkar, U. P., Reiersen, A. M., Todorov, A. A., & Todd, R. D. (2010). Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11. Journal of the American Academy of Child & Adolescent Psychiatry, 49(3), 217-228. Retrieved from /

Rucklidge, J. J. (2010). Gender differences in attention-deficit/hyperactivity disorder. Psychiatric Clinics, 33(2), 357-373. Retrieved from 2

Hodgkins, P., Shaw, M., Coghill, D., & Hechtman, L. (2012). Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. European child & adolescent psychiatry, 21(9), 477-492. doi: 10. 1007/s00787-012-0286-5

Centres for Disease Control and Prevention. (2019). What is ADHD? Retrieved from

Sprich, S. E., Burbridge, J., Lerner, J. A., & Safren, S. A. (2015). Cognitive-behavioral treatment for ADHD in adolescents: Clinical considerations and a series of cases. Cognitive and behavioral practice, 22(2), 116-126. doi: 10.1016/j.cbpra.2015. 01.001

Geffen, J., & Forster, K. (2018). A clinical perspective on adult ADHD treatment. Therapeutic advances in psychopharmacology, 8(1), 25-32. doi: 10. 1177/2045125317734977

Wilens, T. E., & Spencer, T. J. (2010). Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgraduate medicine, 122(5), 97-109. doi: 10.3810/pgm.2010.09. 2206

National Institute for Mental Health. (2019). Attention-Deficit/Hyperactivity Disorder. (2019). Retrieved from.

Bailey, E. (2019). Adderall vs. Ritalin - An ADHD Medication Comparison. ADDitude. Retrieved from /

Sigler, U. (2019). ADHD Looks Different in Women. Here are the reasons and how to do it. ADDitude. Retrieved from /

Storebo, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., ... Gluud, C. (2018, May 9). Assessment of adverse events in non-randomised studies involving methylphenidate in attention deficit hyperactivity disorder (ADHD), in children and teens Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. 2

Faraone, S. V. (2018). The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neuroscience & Biobehavioral Reviews, 87, 255-270. 1

Waite, R. (2010). ADHD in Women: This is not an excuse, but an explanation. Perspectives in Psychiatric Care, 46(3), 182-196. x

Knouse, L. E., & Safren, S. A. (2010). Current status of cognitive behavioral therapy (CBT) for adult attention deficit hyperactivity disorder. Psychiatric Clinics of North America. W.B. Saunders. 1

Parekh, R. (2017). What is ADHD? American Psychiatry Association. Retrieved from d

Davis, N. O., Bower, J., & Kollins, S. H. (2018). A proof-of-concept study on a digital intervention for ADHD in children at home. PLoS ONE, 13(1). 9